2016
Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011)
Arora S, Panaich SS, Patel N, Patel NJ, Lahewala S, Thakkar B, Savani C, Jhamnani S, Singh V, Patel N, Patel S, Sonani R, Patel A, Tripathi B, Deshmukh A, Chothani A, Patel J, Bhatt P, Mohamad T, Remetz MS, Curtis JP, Attaran RR, Mena CI, Schreiber T, Grines C, Cleman M, Forrest JK, Badheka AO. Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011). Catheterization And Cardiovascular Interventions 2016, 88: 605-616. PMID: 26914274, DOI: 10.1002/ccd.26452.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAmputation, SurgicalCross-Sectional StudiesDatabases, FactualDrug CostsEndovascular ProceduresFemaleHospital CostsHospital MortalityHumansLimb SalvageLogistic ModelsLower ExtremityMaleMiddle AgedMultivariate AnalysisOdds RatioPeripheral Arterial DiseasePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPropensity ScoreRisk FactorsTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsGlycoprotein IIb/IIIa inhibitorsPeripheral endovascular interventionsHospital mortalityHospitalization costsEndovascular interventionGPI useAmputation rateUtilization Project Nationwide Inpatient Sample databaseTwo-level hierarchical multivariateIIb/IIIa inhibitorsNationwide Inpatient Sample databaseLower amputation ratesPaucity of dataHospital outcomesPostprocedural complicationsSecondary outcomesPropensity matchingStudy cohortHealthcare costsICD-9Multivariate analysisStudy outcomesSample databaseMortalityHierarchical multivariate
1998
Efficacy of Coronary Stenting Versus Balloon Angioplasty in Small Coronary Arteries fn1fn1This study was supported in part by a grant from Johnson & Johnson Interventional Systems, Inc., Warren, New Jersey.
Savage M, Fischman D, Rake R, Leon M, Schatz R, Penn I, Nobuyoshi M, Moses J, Hirshfeld J, Heuser R, Baim D, Cleman M, Brinker J, Gebhardt S, Goldberg S, Investigators F. Efficacy of Coronary Stenting Versus Balloon Angioplasty in Small Coronary Arteries fn1fn1This study was supported in part by a grant from Johnson & Johnson Interventional Systems, Inc., Warren, New Jersey. Journal Of The American College Of Cardiology 1998, 31: 307-311. PMID: 9462572, DOI: 10.1016/s0735-1097(97)00511-1.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryChi-Square DistributionCohort StudiesCoronary AngiographyCoronary DiseaseCoronary VesselsDisease-Free SurvivalElective Surgical ProceduresEquipment DesignFemaleFollow-Up StudiesHumansLinear ModelsMaleMiddle AgedRecurrenceStentsSurvival RateTreatment OutcomeUnited StatesUnited States Food and Drug AdministrationConceptsElective stent placementBalloon angioplastyCoronary arteryStent placementElective stent implantationJohnson Interventional SystemsPostprocedural lumen diameterPrimary end pointEvent-free survivalClinical event ratesSmall coronary arteriesQuantitative coronary angiographyPalmaz-Schatz stentsAngioplasty groupAngiographic characteristicsCoronary angiographyClinical outcomesNew lesionsProcedural successDiameter stenosisStent groupStent implantationAbrupt closurePatientsAngioplasty
1996
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
Mark D, Talley J, Topol E, Bowman L, Lam L, Anderson K, Jollis J, Cleman M, Lee K, Aversano T, Untereker W, Davidson-Ray L, Califf R. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996, 94: 629-35. PMID: 8772681, DOI: 10.1161/01.cir.94.4.629.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplastyAntibodies, MonoclonalAnticoagulantsAspirinBlood TransfusionCosts and Cost AnalysisDouble-Blind MethodFemaleHeparinHumansImmunoglobulin Fab FragmentsInfusions, IntravenousInjections, IntravenousMaleMiddle AgedMyocardial IschemiaPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecurrenceStentsTreatment OutcomeUnited StatesConceptsHigh-risk coronary angioplastyC7E3 FabIschemic eventsCoronary angioplastyInitial hospitalizationPlatelet glycoprotein IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionAggressive platelet inhibitionBaseline medical costsIschemic end pointsReduced ischemic eventsAcute ischemic eventsCost of therapyEPIC trialMajor bleedingBleeding episodesIschemic complicationsStandard carePlatelet inhibitionHospitalization ratesReceptor antibodiesHospital costsMedical costsMedicare fee
1995
Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experience
Wong S, Baim D, Schatz R, Teirstein P, King S, Curry R, Heuser R, Ellis S, Cleman M, Overlie P, Hirshfeld J, Walker C, Litvack F, Fish D, Brinker J, Buchbinder M, Goldberg S, Chuang Y, Leon M, Group P. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experience. Journal Of The American College Of Cardiology 1995, 26: 704-712. PMID: 7642863, DOI: 10.1016/0735-1097(95)00217-r.Peer-Reviewed Original ResearchConceptsSaphenous vein graft lesionsVein graft lesionsGraft lesionsStent implantationDiameter stenosisStent placementActuarial event-free survivalFavorable late clinical outcomeNative coronary artery diseaseSaphenous vein graft angioplastySaphenous vein graft diseaseImproved long-term outcomesMultivariate logistic regression analysisFrequent periprocedural complicationsLate clinical outcomesStandard balloon angioplastyStent placement resultsVein graft angioplastyEvent-free survivalProcedural success rateOverall restenosis rateVein graft diseaseCoronary artery diseaseReference vessel sizeLong-term outcomes